ABL1 and acute lymphoblastic leukemia: Based on these findings, multiple clinical trials proposed the use of dasatinib with chemotherapy in newly diagnosed pediatric and AYA patients with ABL-class Ph-like B-ALL: the phase 3 COG trial AALL1131 (NCT01406756) and the SJCRH Total XVII trial (NCT03117751).